3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
13
Carcinoid Tumor
5
Gastro-enteropancreatic neuroendocrine tumor
4
Acromegaly
4
Serotonin Syndrome
2
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pheochromocytoma
1
Peritoneal Neoplasms
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Neoplasms
1
Intestinal Obstruction
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Carcinoid Heart Disease
1
Adenoma, Islet Cell
1
Interventions
lanreotide
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Temozolomide
1
Solutions
1
Radiosurgery
1
Microarray Analysis
1
Injections
1
Early Intervention, Educational
1
Diet, Mediterranean
1
Diet, Ketogenic
1
DNA Methylation
1
Complementary Therapies
1
Biological Therapy
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Growth Hormone-Secreting Pituitary Adenoma
×
lanreotide
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled